Refer patients to a geneticist for testing as soon as Morquio A is suspected²

Earlier diagnosis of Morquio A may improve long-term patient outcomes²

- I Common paediatric conditions may signal Morquio A⁶
- I Some ENT manifestations are common in the very early stages of Morquio A⁶
- I A geneticist can perform an enzyme activity analysis to rule out or confirm a diagnosis of Morquio A if these signs are present and persistent in patients²



BOMARIN

Rule out or confirm Morquio A with an enzyme activity analysis²

References: 1. Bhattacharya K, Balasubramaniam S, Choy YS, et al. Overcoming the barriers to diagnosis of Morquio A syndrome. Orphanet J Rare Dis. 2014;9:192. 2. Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A. 2015;167A:11-25. 3. Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165-174. 4. Hendriksz CJ, Harmatz P, Beck M, et al. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2013;110:54-64. 5. Tomatsu S, Montaño AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12:931-945. 6. Mesolella M, Cimmino M, Cantone E, et al. Management of otolaryngological manifestations in mucopolysaccharidoses: our experience. Acta Otorhinolaryngol Ital. 2013;33:267-272. 7. Hendriksz CJ, Al-Jawad M, Berger KI, et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis. 2013;36:309-322. 8. Wood TC, Harvey K, Beck M, et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013;36:309-322. 8. Wood TC, Harvey K, Gottesman S, Metab Dis. 2013;1805-818.

BioMarin Pharmaceutical Australia Pty Ltd

119 Willoughby Rd, Crows Nest, NSW 2065, Ph +61 2 9967 8662, Medical Information 1800 387 876, medinfoasia@bmrn.com © 2017 BioMarin Pharmaceutical Inc. All Rights Reserved. APAC/MPSIV/0017



WOULD YOU SUSPECT MORQUIO A?

BOMARIN

Morquio A can progress to serious complications regardless of phenotype¹

Morquio A is a multisystemic genetic disorder¹

- I Deficient enzyme activity leads to an accumulation of glycosaminoglycans (GAGs), which places patients at risk for progressive organ damage
- I High degree of genetic heterogeneity may be responsible for the wide spectrum of phenotypic presentations

Diverse presentations of Morquio A can complicate patient identification²

- Patients with a nonclassical phenotype can be easily missed, even among specialists¹
- I Diagnosis of Morquio A is often delayed over 2 years due to misdiagnosis^{1,3}

Nonclassical musculoskeletal presentation can include the following^{1,2,4}:

- Potential height of > 140 cm
- I Hip stiffness and pain
- Lack of overt skeletal manifestations

In an international Morquio A registry, 25% of Morquio A patients have a nonclassical phenotype³


Classical musculoskeletal presentation can include the following^{2,5}:

Height of < 120 cm Overt spinal and skeletal abnormalities Chest abnormalities Genu valgum Abnormal gait Joint laxity

Common paediatric conditions may signal Morquio A⁶

Ear, Nose, and Throat (ENT) manifestations are common in the very early stages of Morquio A, and patients may visit their paediatrician or paediatric ENT before being diagnosed^{6,7}

Consider Morquio A in patients who have an occurrence of any of the following signs or symptoms:



Consider Morquio A in patients who have frequent recurrence of or persistence with any of the following signs or symptoms: